Allergy, Asthma & Immunology Research

  • 제10권6호
  • /
  • Pages.662-674
  • /
  • 2018
  • /
  • 2092-7355(pISSN)
  • /
  • 2092-7363(eISSN)
대한천식알레르기학회 (The Korean Academy of Asthma, Allergy and Clinical Immunology)
권호 표지
DOI QR코드

DOI QR Code

Decreased CRTH2 Expression and Response to Allergen Re-stimulation on Innate Lymphoid Cells in Patients With Allergen-Specific Immunotherapy

  • Mitthamsiri, Wat (Division of Allergy and Clinical Immunology, Department of Medicine, Phramongkutklao Hospital) ;
  • Pradubpongsa, Panitan (Division of Allergy and Clinical Immunology, Department of Medicine, Phramongkutklao Hospital) ;
  • Sangasapaviliya, Atik (Division of Allergy and Clinical Immunology, Department of Medicine, Phramongkutklao Hospital) ;
  • Boonpiyathad, Tadech (Division of Allergy and Clinical Immunology, Department of Medicine, Phramongkutklao Hospital)
  • 투고 : 2018.04.28
  • 심사 : 2018.07.10
  • 발행 : 2018.11.01
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: Group 2 innate lymphoid cells (ILC2s) have been implicated in the pathogenesis of allergic disease. However, the effect of allergen-specific immunotherapy (AIT) on ILCs remains to be clarified. The aim of this study was to evaluate the levels of ILC subsets in allergic rhinitis (AR) patients in response to house dust mite (HDM)-specific immunotherapy. Methods: We enrolled 37 AR patients undergoing AIT (16 responders and 11 non-responders) for 2 years, 35 HDM AR patients and 28 healthy subjects. Peripheral blood mononuclear cells (PBMCs) were analyzed by flow cytometry to identify ILC subsets. Stimulation of ILC2s with recombinant allergen-specific protein was used to determine ILC2's activation (CD69 expression). Results: Responder AIT patients and healthy subjects had a decreased frequency of circulating ILC2s compared to non-responder AIT and AR patients. Conversely, ILC1s from responder AIT patients and healthy subjects showed increased frequency compared to non-responder AIT and AR patients. The frequency of ILC3s natural cytotoxicity receptor $(NCR)^+$ and $NCR^-$ in responder AIT patients was significantly lower compared to AR patients and healthy subjects. The ILC1: ILC2 proportion in responder AIT patients was similar to that of healthy subjects. PBMCs from patients who were responders to AIT had a significantly lower expression of the activation marker CD69 on ILC2s in response to allergen re-stimulation compared to AR patients, but no difference compared to non-responder AIT patients and healthy subjects. Conclusions: We propose that AIT might affect ILC responses. The activation of ILC2s was reduced in AR patients treated with AIT. Our results indicate that a relative ILC1/ILC2 skewed response is a possible key to successful AIT.

키워드

과제정보

연구 과제 주관 기관 : Phramongkutklao Hospital, Phramongkutklao College of Medicine

참고문헌

  1. Morita H, Moro K, Koyasu S. Innate lymphoid cells in allergic and nonallergic inflammation. J Allergy Clin Immunol 2016;138:1253-64. https://doi.org/10.1016/j.jaci.2016.09.011
  2. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells--a proposal for uniform nomenclature. Nat Rev Immunol 2013;13:145-9. https://doi.org/10.1038/nri3365
  3. Bernink JH, Peters CP, Munneke M, te Velde AA, Meijer SL, Weijer K, et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol 2013;14:221-9. https://doi.org/10.1038/ni.2534
  4. Fuchs A, Vermi W, Lee JS, Lonardi S, Gilfillan S, Newberry RD, et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-$\gamma$-producing cells. Immunity 2013;38:769-81. https://doi.org/10.1016/j.immuni.2013.02.010
  5. Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H, et al. Innate production of $T_H2$ cytokines by adipose tissue-associated $c-Kit^+Sca-1^+$ lymphoid cells. Nature 2010;463:540-4. https://doi.org/10.1038/nature08636
  6. Mjosberg JM, Trifari S, Crellin NK, Peters CP, van Drunen CM, Piet B, et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 2011;12:1055-62. https://doi.org/10.1038/ni.2104
  7. Price AE, Liang HE, Sullivan BM, Reinhardt RL, Eisley CJ, Erle DJ, et al. Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci U S A 2010;107:11489-94. https://doi.org/10.1073/pnas.1003988107
  8. Mjosberg J, Bernink J, Golebski K, Karrich JJ, Peters CP, Blom B, et al. The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. Immunity 2012;37:649-59. https://doi.org/10.1016/j.immuni.2012.08.015
  9. Pelly VS, Kannan Y, Coomes SM, Entwistle LJ, Ruckerl D, Seddon B, et al. IL-4-producing ILC2s are required for the differentiation of $T_H2$ cells following Heligmosomoides polygyrus infection. Mucosal Immunol 2016;9:1407-17. https://doi.org/10.1038/mi.2016.4
  10. Melo-Gonzalez F, Hepworth MR. Functional and phenotypic heterogeneity of group 3 innate lymphoid cells. Immunology 2017;150:265-75. https://doi.org/10.1111/imm.12697
  11. Bartemes KR, Kephart GM, Fox SJ, Kita H. Enhanced innate type 2 immune response in peripheral blood from patients with asthma. J Allergy Clin Immunol 2014;134:671-678.e4. https://doi.org/10.1016/j.jaci.2014.06.024
  12. Liu T, Wu J, Zhao J, Wang J, Zhang Y, Liu L, et al. Type 2 innate lymphoid cells: a novel biomarker of eosinophilic airway inflammation in patients with mild to moderate asthma. Respir Med 2015;109:1391-6. https://doi.org/10.1016/j.rmed.2015.09.016
  13. Smith SG, Chen R, Kjarsgaard M, Huang C, Oliveria JP, O'Byrne PM, et al. Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. J Allergy Clin Immunol 2016;137:75-86.e8. https://doi.org/10.1016/j.jaci.2015.05.037
  14. Nagakumar P, Denney L, Fleming L, Bush A, Lloyd CM, Saglani S. Type 2 innate lymphoid cells in induced sputum from children with severe asthma. J Allergy Clin Immunol 2016;137:624-626.e6. https://doi.org/10.1016/j.jaci.2015.06.038
  15. Morita H, Arae K, Unno H, Miyauchi K, Toyama S, Nambu A, et al. An interleukin-33-mast cell-interleukin-2 axis suppresses papain-induced allergic inflammation by promoting regulatory T cell numbers. Immunity 2015;43:175-86. https://doi.org/10.1016/j.immuni.2015.06.021
  16. Halim TY, Krauss RH, Sun AC, Takei F. Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. Immunity 2012;36:451-63. https://doi.org/10.1016/j.immuni.2011.12.020
  17. Bartemes KR, Iijima K, Kobayashi T, Kephart GM, McKenzie AN, Kita H. IL-33-responsive lineage-$CD25^+CD44^{hi}$ lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J Immunol 2012;188:1503-13. https://doi.org/10.4049/jimmunol.1102832
  18. Chang YJ, Kim HY, Albacker LA, Baumgarth N, McKenzie AN, Smith DE, et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol 2011;12:631-8. https://doi.org/10.1038/ni.2045
  19. Kim DW, Cho SH. Emerging endotypes of chronic rhinosinusitis and its application to precision medicine. Allergy Asthma Immunol Res 2017;9:299-306. https://doi.org/10.4168/aair.2017.9.4.299
  20. Doherty TA, Scott D, Walford HH, Khorram N, Lund S, Baum R, et al. Allergen challenge in allergic rhinitis rapidly induces increased peripheral blood type 2 innate lymphoid cells that express CD84. J Allergy Clin Immunol 2014;133:1203-1205.e7. https://doi.org/10.1016/j.jaci.2013.12.1086
  21. Lao-Araya M, Steveling E, Scadding GW, Durham SR, Shamji MH. Seasonal increases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy. J Allergy Clin Immunol 2014;134:1193-1195.e4. https://doi.org/10.1016/j.jaci.2014.07.029
  22. Lombardi V, Beuraud C, Neukirch C, Moussu H, Morizur L, Horiot S, et al. Circulating innate lymphoid cells are differentially regulated in allergic and nonallergic subjects. J Allergy Clin Immunol 2016;138:305-8. https://doi.org/10.1016/j.jaci.2015.12.1325
  23. Zhong H, Fan XL, Yu QN, Qin ZL, Chen D, Xu R, et al. Increased innate type 2 immune response in house dust mite-allergic patients with allergic rhinitis. Clin Immunol 2017;183:293-9. https://doi.org/10.1016/j.clim.2017.09.008
  24. Fan D, Wang X, Wang M, Wang Y, Zhang L, Li Y, et al. Allergen-dependent differences in ILC2s frequencies in patients with allergic rhinitis. Allergy Asthma Immunol Res 2016;8:216-22. https://doi.org/10.4168/aair.2016.8.3.216
  25. Caraballo L, Zakzuk J, Lee BW, Acevedo N, Soh JY, Sanchez-Borges M, et al. Particularities of allergy in the Tropics. World Allergy Organ J 2016;9:20. https://doi.org/10.1186/s40413-016-0110-7
  26. Tham EH, Lee AJ, Bever HV. Aeroallergen sensitization and allergic disease phenotypes in Asia. Asian Pac J Allergy Immunol 2016;34:181-9.
  27. Wise SK, Lin SY, Toskala E, Orlandi RR, Akdis CA, Alt JA, et al. International consensus statement on allergy and rhinology: allergic rhinitis. Int Forum Allergy Rhinol 2018;8:108-352.
  28. Calderon MA, Bousquet J, Canonica GW, Cardell LO, Fernandez de Rojas DH, Kleine-Tebbe J, et al. Guideline recommendations on the use of allergen immunotherapy in house dust mite allergy: Time for a change? J Allergy Clin Immunol 2017;140:41-52. https://doi.org/10.1016/j.jaci.2017.01.049
  29. Jutel M, Kosowska A, Smolinska S. Allergen immunotherapy: past, present, and future. Allergy Asthma Immunol Res 2016;8:191-7. https://doi.org/10.4168/aair.2016.8.3.191
  30. Fan DC, Wang XD, Wang CS, Wang Y, Cao FF, Zhang L. Suppression of Immunotherapy on group 2 innate lymphoid cells in allergic rhinitis. Chin Med J (Engl) 2016;129:2824-8. https://doi.org/10.4103/0366-6999.194642
  31. Cosmi L, Liotta F, Maggi L, Annunziato F. Role of type 2 innate lymphoid cells in allergic diseases. Curr Allergy Asthma Rep 2017;17:66. https://doi.org/10.1007/s11882-017-0735-9
  32. Xu G, Zhang L, Wang DY, Xu R, Liu Z, Han DM, et al. Opposing roles of IL-17A and IL-25 in the regulation of TSLP production in human nasal epithelial cells. Allergy 2010;65:581-9. https://doi.org/10.1111/j.1398-9995.2009.02252.x
  33. Asaka D, Yoshikawa M, Nakayama T, Yoshimura T, Moriyama H, Otori N. Elevated levels of interleukin-33 in the nasal secretions of patients with allergic rhinitis. Int Arch Allergy Immunol 2012;158 Suppl 1:47-50. https://doi.org/10.1159/000337764
  34. Kato Y, Akasaki S, Muto-Haenuki Y, Fujieda S, Matsushita K, Yoshimoto T. Nasal sensitization with ragweed pollen induces local-allergic-rhinitis-like symptoms in mice. PLoS One 2014;9:e103540. https://doi.org/10.1371/journal.pone.0103540
  35. Sohn MH. Efficacy and safety of subcutaneous allergen immunotherapy for allergic rhinitis. Allergy Asthma Immunol Res 2018;10:1-3. https://doi.org/10.4168/aair.2018.10.1.1
  36. Park KH, Son M, Choi SY, Park HJ, Lee JH, Jeong KY, et al. Erratum: In vitro evaluation of allergen potencies of commercial house dust mite sublingual immunotherapy reagents. Allergy Asthma Immunol Res 2017;9:187. https://doi.org/10.4168/aair.2017.9.2.187
  37. Lee JH, Kim SC, Choi H, Jung CG, Ban GY, Shin YS, et al. A retrospective study of clinical response predictors in subcutaneous allergen immunotherapy with house dust mites for allergic rhinitis. Allergy Asthma Immunol Res 2018;10:18-24. https://doi.org/10.4168/aair.2018.10.1.18
  38. Smarr CB, Bryce PJ, Miller SD. Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases. Crit Rev Immunol 2013;33:389-414. https://doi.org/10.1615/CritRevImmunol.2013007046
  39. Wawrzyniak M, O'Mahony L, Akdis M. Role of regulatory cells in oral tolerance. Allergy Asthma Immunol Res 2017;9:107-15. https://doi.org/10.4168/aair.2017.9.2.107
  40. Kuipers H, Heirman C, Hijdra D, Muskens F, Willart M, van Meirvenne S, et al. Dendritic cells retrovirally overexpressing IL-12 induce strong Th1 responses to inhaled antigen in the lung but fail to revert established Th2 sensitization. J Leukoc Biol 2004;76:1028-38. https://doi.org/10.1189/jlb.0604325
  41. Krishnamoorthy N, Burkett PR, Dalli J, Abdulnour RE, Colas R, Ramon S, et al. Cutting edge: maresin-1 engages regulatory T cells to limit type 2 innate lymphoid cell activation and promote resolution of lung inflammation. J Immunol 2015;194:863-7. https://doi.org/10.4049/jimmunol.1402534
  42. Rigas D, Lewis G, Aron JL, Wang B, Banie H, Sankaranarayanan I, et al. Type 2 innate lymphoid cell suppression by regulatory T cells attenuates airway hyperreactivity and requires inducible T-cell costimulator-inducible T-cell costimulator ligand interaction. J Allergy Clin Immunol 2017;139:1468-1477.e2. https://doi.org/10.1016/j.jaci.2016.08.034
  43. Doherty TA, Broide DH. Group 2 innate lymphoid cells: new players in human allergic diseases. J Investig Allergol Clin Immunol 2015;25:1-11.
  44. Bal SM, Bernink JH, Nagasawa M, Groot J, Shikhagaie MM, Golebski K, et al. IL-$1{\beta}$, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs. Nat Immunol 2016;17:636-45. https://doi.org/10.1038/ni.3444
  45. Li CW, Lu HG, Chen DH, Lin ZB, Wang DY, Li TY. In vivo and in vitro studies of Th17 response to specific immunotherapy in house dust mite-induced allergic rhinitis patients. PLoS One 2014;9:e91950. https://doi.org/10.1371/journal.pone.0091950
  46. Gueguen C, Bouley J, Moussu H, Luce S, Duchateau M, Chamot-Rooke J, et al. Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy. J Allergy Clin Immunol 2016;137:545-58. https://doi.org/10.1016/j.jaci.2015.09.015
  47. von Burg N, Turchinovich G, Finke D. Maintenance of immune homeostasis through ILC/T cell interactions. Front Immunol 2015;6:416.
  48. Sugita K, Steer CA, Martinez-Gonzalez I, Altunbulakli C, Morita H, Castro-Giner F, et al. Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients. J Allergy Clin Immunol 2018;141:300-310.e11. https://doi.org/10.1016/j.jaci.2017.02.038
  49. Kelly E, Won A, Refaeli Y, Van Parijs L. IL-2 and related cytokines can promote T cell survival by activating AKT. J Immunol 2002;168:597-603. https://doi.org/10.4049/jimmunol.168.2.597
  50. Seehus CR, Kadavallore A, Torre B, Yeckes AR, Wang Y, Tang J, et al. Alternative activation generates IL-10 producing type 2 innate lymphoid cells. Nat Commun 2017;8:1900. https://doi.org/10.1038/s41467-017-02023-z

피인용 문헌

  1. Innate Lymphoid Cells in Mucosal Immunity vol.10, pp.None, 2018, https://doi.org/10.3389/fimmu.2019.00861
  2. Recent developments and highlights in immune monitoring of allergen immunotherapy vol.74, pp.12, 2018, https://doi.org/10.1111/all.14078
  3. Impact of high‐altitude therapy on type‐2 immune responses in asthma patients vol.75, pp.1, 2018, https://doi.org/10.1111/all.13967
  4. Mechanisms of Allergen Immunotherapy in Allergic Rhinitis vol.21, pp.1, 2021, https://doi.org/10.1007/s11882-020-00977-7
  5. Sublingual Immunotherapy: How Sublingual Allergen Administration Heals Allergic Diseases; Current Perspective about the Mode of Action vol.10, pp.2, 2018, https://doi.org/10.3390/pathogens10020147
  6. IL-10–producing innate lymphoid cells increased in patients with house dust mite allergic rhinitis following immunotherapy vol.147, pp.4, 2018, https://doi.org/10.1016/j.jaci.2020.10.029
  7. Characteristics of tissue-resident ILCs and their potential as therapeutic targets in mucosal and skin inflammatory diseases vol.76, pp.11, 2018, https://doi.org/10.1111/all.14863